R-FCM

None

FDA approved use on chronic lymphocytic leukemia.

This drug should be coded

None

None

December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.

FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.

FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.

FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.

FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.

June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.


.

This drug should be coded

None

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

This drug should be coded